Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 7Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Myeloproliferative Disorders 3Bronchiolitis Obliterans Syndrome 3Blast Crisis 3Neoplasms, Plasma Cell 2Neoplasms 2Mastocytosis, Systemic 2Lymphoma 2Lymphohistiocytosis, Hemophagocytic 2Leukemia, Myeloid, Chronic-Phase 2Hematologic Diseases 2Graft vs Host Disease 2Anemia, Aplastic 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Thrombocytopenia 1Thalassemia 1Recurrence 1Purpura, Thrombocytopenic, Idiopathic 1Primary Myelofibrosis 1Piebaldism 1Philadelphia Chromosome 1Patient Compliance 1Pathologic Processes 1Oligodendroglioma 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Mast Cell Activation Disorders × Myeloid × Clear all
NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 4 Completed
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡